Comparative safety of antimuscarinics versus mirabegron for overactive bladder in Parkinson disease

Overactive bladder (OAB) is a common non-motor symptom of Parkinson disease (PD), often treated with antimuscarinics or beta-3 agonists. There is lack of evidence to guide OAB management in PD. To assess the comparative safety of antimuscarinics versus beta-3 agonists for OAB treatment in PD. We emp...

Full description

Saved in:
Bibliographic Details
Published in:Parkinsonism & related disorders 2023-10, Vol.115, p.105822-105822, Article 105822
Main Authors: Abraham, Danielle S., Pham Nguyen, Thanh Phuong, Newcomb, Craig W., Gray, Shelly L., Hennessy, Sean, Leonard, Charles E., Liu, Qing, Weintraub, Daniel, Willis, Allison W.
Format: Article
Language:English
Subjects:
Acetanilides - therapeutic use
Aged
Anticholinergics
Antimuscarinics
Cholinergic Antagonists - adverse effects
Cohort Studies
Humans
Medicare
Mirabegron
Muscarinic Antagonists - adverse effects
Overactive bladder
Parkinson disease
Parkinson Disease - complications
Parkinson Disease - drug therapy
Prospective Studies
Treatment Outcome
United States
Urinary Bladder, Overactive - diagnosis
Urological Agents - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Overactive bladder (OAB) is a common non-motor symptom of Parkinson disease (PD), often treated with antimuscarinics or beta-3 agonists. There is lack of evidence to guide OAB management in PD. To assess the comparative safety of antimuscarinics versus beta-3 agonists for OAB treatment in PD. We employed a new-user, active-comparator cohort study design. We included Medicare beneficiaries age ≥65 years with PD who were new users of either antimuscarinic or beta-3 agonist. The primary outcome was any acute care encounter (i.e., non-elective hospitalization or emergency department visit) within 90 days of OAB drug initiation. The main secondary outcome was a composite measure of acute care encounters for anticholinergic related adverse events (AEs). Matching on high-dimensional propensity score (hdPS) was used to address potential confounding. We used Cox proportional hazards models to examine the association between OAB drug category and outcomes. We repeated analyses for 30- and 180-day follow-up periods. We identified 27,091 individuals meeting inclusion criteria (mean age: 77.8 years). After hdPS matching, antimuscarinic users had increased risks for any acute care encounter (hazard ratio [HR] 1.23, 95% confidence interval [CI] 1.12–1.37) and encounters for anticholinergic related AEs (HR 1.18, 95% CI 1.04–1.34) compared to beta-3 agonist users. Similar associations were observed for sensitivity analyses. Among persons with PD, anticholinergic initiation was associated with a higher risk of acute care encounters compared with beta-3 agonist initiation. The long-term safety of anticholinergic vs. beta-3 agonist therapy in the PD population should be evaluated in a prospective study. •Overactive bladder (OAB) is a common non-motor symptom of Parkinson disease (PD).•There is lack of safety data of antimuscarinics vs. mirabegron for OAB treatment.•Antimuscarinics were associated with greater acute care event risks vs. mirabegron.•Long-term safety of these agents in PD should be evaluated in a prospective study.
ISSN:1353-8020
1873-5126
DOI:10.1016/j.parkreldis.2023.105822